RecruitingPhase 3NCT06451757
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Studying Mitochondrial disorder due to a defect in assembly or maturation of the respiratory chain complexes
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Khondrion BV
- Intervention
- Sonlicromanol(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (10)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Cleveland Clinic Neurological Institute Mellen Center, Cleveland, Ohio, United States
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
- Rigshospitalet, University of Copenhagen, Kopenhagen, Region Sjælland, Denmark
- CHU de Bordeaux - Hôpital Pellegrin Service Gynecologie Obstetrique, Bordeaux, Gironde, France
- Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est, Paris, Paris, France
- Klinikum der Universität München Friedrich-Baur-Institut, München, Germany
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Milano, Italy
- Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
- University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, Greater London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06451757 on ClinicalTrials.govOther trials for Mitochondrial disorder due to a defect in assembly or maturation of the respiratory chain complexes
Additional recruiting or active studies for the same condition.